Blood Pressure Medication Losartan-HCTZ Recalled for Impurity Deviation
Direct Rx is recalling 81 bottles of Losartan Potassium and Hydrochlorothiazide 100/12.5 mg due to AZIDO impurity exceeding acceptable manufacturing standards. Affected bottles were distributed in Alabama, Georgia, Florida, and Louisiana.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a pharmaceutical product with a manufacturing defect (impurity exceeding acceptable limits) creating potential risk of harm. No illnesses or injuries have been reported in the source material. The hazard is a defined risk without demonstrated patient impact, justifying a High severity classification.
Plain-English summary
Direct Rx is recalling 81 bottles of Losartan Potassium and Hydrochlorothiazide 100/12.5 mg tablets due to CGMP deviations. Testing revealed AZIDO impurity levels above acceptable manufacturing limits. The medication was manufactured by Lupin Pharmaceuticals, Inc. and distributed by Direct Rx.
The affected bottles were distributed in Alabama, Georgia, Florida, and Louisiana. Consumers in these states who have the recalled medication should check their bottles against the affected lot numbers: 11MY2103, 05JA2106, 20MY2115, 22JU2118, 29JY2113, and 13SE2113, which appear in both 30-count (NDC 72189-167-30) and 90-count (NDC 72189-167-90) bottles.
Patients taking this medication should not abruptly discontinue use. Contact your healthcare provider or pharmacist for guidance on next steps, which may include verifying your lot number and obtaining replacement medication if needed.
The recalled product
- Product
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)
- Brand
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Manufacturer
- Direct Rx
- Category
- Drug — Antihypertensive
- Affected units
- 81
Distribution
Related recalls
Same brand · LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- HighLosartan Potassium and Hydrochlorothiazide Tablets Recalled for Foreign Plastic Contamination
FDA (Drugs) · 2024-05-22
- HighFDA Recalls Losartan-Hydrochlorothiazide Tablets for Manufacturing Quality Deviations
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium and Hydrochlorothiazide Recall: Impurity Levels Above Acceptable Limits
FDA (Drugs) · 2022-06-01
- HighBlood Pressure Medication Recalled for Manufacturing Impurity
FDA (Drugs) · 2022-06-01
- HighBlood pressure medication Losartan and hydrochlorothiazide recalled for elevated azido impurity
FDA (Drugs) · 2022-06-01
Same manufacturer · Direct Rx
See all →- ModerateDuloxetine 30 mg capsules recalled for impurity above FDA limits
FDA (Drugs) · 2026-07-01
- HighDuloxetine delayed-release capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- HighDirect Rx duloxetine 30 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-13
- ModerateCiprofloxacin Ophthalmic Solution Recalled for Defective Container Cap
FDA (Drugs) · 2025-04-23
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
Same hazard · azido impurity
See all →- HighLosartan Potassium Tablets Recalled for Elevated AZIDO Impurity Levels
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for Manufacturing Impurity Issues
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium tablets recalled for elevated AZIDO impurity
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for CGMP Deviations and Elevated Impurity
FDA (Drugs) · 2022-06-08
- HighLosartan HCTZ drug recall due to azido impurity levels above limits
FDA (Drugs) · 2022-06-01